Migraine

>

Latest News

Atogepant Improves QoL, Function in Adults with Chronic, Episodic, Treatment-Resistant Migraine / image credit Christopher Gottschalk, MD courtesy of Yale Medicine
Atogepant Improves QoL, Function in Adults with Chronic, Episodic, Treatment-Resistant Migraine

December 10th 2024

An analysis of patient reported outcome measures from 3 pivotal phase 3 RCTs of atogepant 60 mg demonstrates efficacy across functional domains as well as for migraine prevention.

 Fremanezumab Safe and Effective for Prevention of Episodic Migraine in Children: Phase 3 Data Announced / image credit courtesy of Vall d'Hebron
Fremanezumab Safe and Effective for Prevention of Episodic Migraine in Children: Phase 3 Data Announced

December 5th 2024

Novel DHE Nasal Spray for Acute Treatment of Migraine: Daily Dose / image credit: ©New Africa/AdobeStock
Novel DHE Nasal Spray for Acute Treatment of Migraine: Daily Dose

October 29th 2024

Novel PACAP-Targeted Antibody Reduces Monthly Migraine Days in Phase 2 HOPE Trial
Novel PACAP-Targeted Antibody Reduces Monthly Migraine Days in Phase 2 HOPE Trial

October 21st 2024

Novel DHE Nasal Spray Safe, Effective For Acute Treatment of Migraine in Long-Term Safety Trial / image credit migraine concept: ©Mobic/Shutterstock.com
Novel DHE Nasal Spray Safe, Effective For Acute Treatment of Migraine in Long-Term Safety Trial

October 15th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.